Literature DB >> 7541291

Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule.

L Cagnon1, M Cucchiarini, J C Lefebvre, A Doglio.   

Abstract

Adenovirus VA1 gene is efficiently transcribed by RNA polymerase III and gives rise to a small highly ordered RNA. To inhibit replication of human immunodeficiency virus (HIV), a chimeric VA1 RNA molecule was designed that contained a short antisense RNA sequence complementary to a conserved region of the HIV-1 rev encoding mRNA (28 nucleotides). This sequence, which was inserted into a projecting loop of the VA1 RNA central domain, was mainly single stranded and available for binding with its complementary sequence. The chimeric VA1 antisense was abundantly expressed in human cells constituting 3% of mRNA and promoted strong and specific inhibition of HIV-1 gene replication. The stable expression of antisense RNA in human T cells (CEM) protected these cells from HIV-1 multiplication for at least 3 months. No side effects were detected because of the lack of antisense effect upon replication of the closely related HIV-2. The VA1 gene may provide a suitably compact gene cassette for the intracellular expression of short antisense RNA directed against HIV.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541291

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  2 in total

1.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy.

Authors:  C M Browning; L Cagnon; P D Good; J Rossi; D R Engelke; D M Markovitz
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model.

Authors:  D S Kernodle; R K Voladri; B E Menzies; C C Hager; K M Edwards
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.